# Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.

> **NCT06332339** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 45 (actual)

## Conditions studied

- HIV

## Interventions

- **BIOLOGICAL:** 16055 NFL delta Gly4 trimer
- **BIOLOGICAL:** Trimer 4571
- **BIOLOGICAL:** Ad4-Env145NFL, 5 x 108 viral particles (vp)

## Key facts

- **NCT ID:** NCT06332339
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-15
- **Primary completion:** 2026-11-11
- **Final completion:** 2026-11-11
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2024-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06332339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06332339, "Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT06332339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*